Multi-center Study to Transplant Hepatitis-C Infected Kidneys
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 90
Summary
- Conditions
- Hepatitis C
- Renal Failure Chronic
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 21 years and 65 years
- Gender
- Both males and females
Description
The study objective is to determine if the administration of the direct acting antiviral glecaprevir/pibrentasvir for 8 weeks after kidney transplantation is both safe and effective at preventing the spread of HCV infection from donor kidney with known HCV infection (all genotypes) to an HCV negativ...
The study objective is to determine if the administration of the direct acting antiviral glecaprevir/pibrentasvir for 8 weeks after kidney transplantation is both safe and effective at preventing the spread of HCV infection from donor kidney with known HCV infection (all genotypes) to an HCV negative recipient as evidenced by a negative HCV viral RNA at 12 weeks post treatment.
Tracking Information
- NCT #
- NCT03781726
- Collaborators
- AbbVie
- University of Pennsylvania
- Johns Hopkins University
- University of Cincinnati
- Weill Medical College of Cornell University
- University of Michigan
- Northwestern University
- Investigators
- Principal Investigator: Raymond T Chung, MD Massachusetts General Hospital
Get Well Soon